The study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

Design Therapeutics is starting a new clinical trial of Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.

The clinical trial started in March 7, 2022 and will continue throughout December 31, 2022.

Primary Outcome Measure: will be primary outcome measure. Frequency of treatment emergent adverse events (TEAEs).

The contacts and locations are the Clinilabs, Eatontown, New Jersey, United States. For more details: https://ichgcp.net/clinical-trials-registry/NCT05285540.